Advertisement

Current HIV/AIDS Reports

, Volume 4, Issue 3, pp 114–118 | Cite as

Managing HIV peripheral neuropathy

  • Alejandra Gonzalez-Duarte
  • Katia Cikurel
  • David M. Simpson
Article

Abstract

Peripheral nerve disorders are frequent complications of HIV disease. Distal symmetrical polyneuropathy (DSP) is the most common peripheral nerve disorder associated with HIV and occurs in over one third of infected patients but may occur in up to 67% if asymptomatic patients are included. Risk factors for DSP include increased age, advanced HIV disease, and history of “d-drugs” or other neurotoxic drugs. The primary manifestations of polyneuropathy are slowly progressive numbness and paresthesias, with burning sensations in the feet usually in a symmetrical pattern. The etiology of HIV-associated DSP is unknown, although neurotoxic effects of cytokines, toxicity of HIV proteins, and mitochondrial damage have been implicated. The current treatment for HIV-associated DSP is symptomatic, with pain modifying medications, including anti-inflammatory agents, opioids, antidepressants, antiepileptics, topical anesthetics, and capsaicin. Sustained virologic control may improve DSP. Novel therapies such as acetyl-l-carnitine or neurotrophic factors are being studied for treatment of DSP.

Keywords

Capsaicin Duloxetine Vira Distal Symmetrical Polyneuropathy Distal Sensory Polyneuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Schifitto G, McDermott MP, McArthur JC, et al.: Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002, 58:1764–1768.PubMedGoogle Scholar
  2. 2.
    Lichtenstein KA, Armon C, Baron A, et al.: Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005, 40:148–157.PubMedCrossRefGoogle Scholar
  3. 3.
    Schifitto G, McDermott MP, McArthur JC, et al.: Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005, 64:842–848.PubMedGoogle Scholar
  4. 4.
    Simpson DM, Olney RK: Peripheral neuropathies associated with human immunodeficiency virus infection. Neurol Clin 1992, 10:685–711.PubMedGoogle Scholar
  5. 5.
    Estanislao L, Thomas D, Simpson D: HIV neuromuscular disease and mitochondrial function. Mitochondrion 2004, 4:131–139.PubMedCrossRefGoogle Scholar
  6. 6.
    Estanislao L, Morgello S, Dorfman D, et al.: Diagnosis of HIV-associated distal symmetric polyneuropathy in the primary care setting [poster]. Presented at the 5th International Society of Neurovirology HIV Symposium. Baltimore, MD; September 2–6, 2003.Google Scholar
  7. 7.
    Martin C, Solders G, Sonnerborg A, Hansson P: Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000, 54:2120–2127.PubMedGoogle Scholar
  8. 8.
    So YT, Holtzman DM, Abrams DI, Olney RK: Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988, 45:945–948.PubMedGoogle Scholar
  9. 9.
    Morgello S, Estanislao L, Simpson D, et al.: HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: The Manhattan HIV brain bank. Arch Neurol 2004, 61:546–551.PubMedCrossRefGoogle Scholar
  10. 10.
    Tagliati M, Grinnell J, Godbold J, Simpson DM: Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999, 56:84–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Childs EA, Lyles RH, Selnes OA, et al.: Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999, 52:607–613.PubMedGoogle Scholar
  12. 12.
    Cornblath DR, McArthur JC: Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988, 38:794–796.PubMedGoogle Scholar
  13. 13.
    Cherry CL, Wesselingh SL, Lal L, McArthur JC: Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005, 65:1778–1781.PubMedCrossRefGoogle Scholar
  14. 14.
    Verma S, Estanislao L, Simpson D: HIV-associated neuropathic pain: Epidemiology, pathophysiology and management. CNS Drugs 2005, 19:325–334.PubMedCrossRefGoogle Scholar
  15. 15.
    Simpson DM, Tagliati M: Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:153–161.PubMedGoogle Scholar
  16. 16.
    Simpson DM, Kitch D, Evans SR, et al.: HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006, 66:1679–1687.PubMedCrossRefGoogle Scholar
  17. 17.
    Pardo CA, McArthur JC, Griffin JW: HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001, 6:21–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Simpson DM: Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002, 8(Suppl 2):33–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Grond S, Zech D, Schug SA, et al.: Validation of world health organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991, 6:411–422.PubMedCrossRefGoogle Scholar
  20. 20.
    Verma S, Estanislao L, Mintz L, Simpson D: Controlling neuropathic pain in HIV. Curr HIV/AIDS Rep 2004, 1:136–141.PubMedCrossRefGoogle Scholar
  21. 21.
    Kieburtz K, Simpson D, Yiannoutsos C, et al.: A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS clinical trial group 242 protocol team. Neurology 1998, 51:1682–1688.PubMedGoogle Scholar
  22. 22.
    Hahn K, Arendt G, Braun JS, et al.: A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004, 251:1260–1266.PubMedCrossRefGoogle Scholar
  23. 23.
    Simpson DM, McArthur JC, Olney R, et al.: Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003, 60:1508–1514.PubMedGoogle Scholar
  24. 24.
    Richter RW, Portenoy R, Sharma U, et al.: Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253–260.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628–638.PubMedCrossRefGoogle Scholar
  26. 26.
    Simpson D, Brown S, Sampson JL: Novel high-concentration capsaicin patch for the treatment of painful HIV-associated distal symmetrical polyneuropathy: results of an open label trial. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8–11, 2004.Google Scholar
  27. 27.
    Simpson DM, Brown SJ, Chang S, and the NGX-400 Study Group: Controlled study of high-concentration capsaicin patch for painful HIV-associated distal sensory polyneuropathy. Presented at the 13th Conference on Retroziruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.Google Scholar
  28. 28.
    Hart AM, Wilson AD, Montovani C, et al.: Acetyl-L-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004, 18:1549–1560.PubMedCrossRefGoogle Scholar
  29. 29.
    Scarpini E, Sacilotto G, Baron P, et al.: Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997, 2:250–252.PubMedGoogle Scholar
  30. 30.
    Keswani SC, Leitz GJ, Hoke A: Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004, 371:102–105.PubMedCrossRefGoogle Scholar
  31. 31.
    Pradat PF: Treatment of peripheral neuropathies with neutrotrophic factors: animal models and clinical trials. Rev Neurol (Paris) 2003, 159:147–161.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Alejandra Gonzalez-Duarte
  • Katia Cikurel
  • David M. Simpson
    • 1
  1. 1.Department of Clinical NeurophysiologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations